XERS · Xeris Biopharma Holdings, Inc.
$8.21
+0.37% last session
End-of-day data · updated 2026-07-29
Market cap
$1B
Enterprise value
$2B
Trailing P/E
117.7
Forward P/E
21.0
Dividend yield
—
Beta
0.85
Avg volume
2M
Employees
0K
2D change
0.37%
5D change
—
10D change
-6.36%
30D change
6.46%
60D change
33.77%
MTD change
3.00%
YTD change
4.97%
Analyst Outlook
Analyst estimates change daily — follow the shifts on the Estimate Trends page.
Technical Analysis
Analyst sentiment over time — XERS
Rec Mean (blue, left — higher = more bullish) vs. price targets (right).
Investment Bank Ratings as of 2026-03-02
Latest call per bank · past 12 months
Barclays
Overweight$9.00
+9.6% vs priceRecent rating actions
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-03-02 | HC Wainwright & Co. | Reiterates | Buy | $10.00 |
| 2026-01-09 | HC Wainwright & Co. | Reiterates | Buy | $10.00 |
| 2025-12-09 | Barclays | Initiates | Overweight | $0.00 → $9.00 |
| 2025-11-07 | Oppenheimer | Maintains | Outperform | $18.00 |
| 2025-11-07 | HC Wainwright & Co. | Maintains | Buy | $10.00 |
| 2025-11-07 | Piper Sandler | Maintains | Neutral | $6.00 → $8.00 |
| 2025-10-29 | Oppenheimer | Maintains | Outperform | $8.00 → $18.00 |
| 2025-09-17 | HC Wainwright & Co. | Maintains | Buy | $10.00 |
Ratings and price targets are the published opinions of the issuing banks, compiled from Yahoo Finance rating actions — not investment advice.
Signal Summary as of 2026-07-28
- RSI (14): RSI is 54 — neutral momentum, neither overbought nor oversold.
- Price vs 50-day MA: Trading 13.2% above the 50-day MA ($7.28).
- Price vs 200-day MA: Trading 16.4% above the 200-day MA ($7.08).
- MA cross: The 50-day MA sits above the 200-day MA (golden-cross regime) — the longer-term trend points up.
- MACD (12,26,9): MACD histogram is negative (-0.10) — short-term momentum is fading.
- 52-week range: Price sits between the 52-week low ($5.00) and high ($9.90).
XERS Price Chart
Loading chart for XERS…
Fundamentals
About Xeris Biopharma Holdings, Inc.
Xeris Biopharma Holdings, Inc., a commercial-stage biopharmaceutical company, engages in developing and commercializing therapies for chronic endocrine and neurological diseases in Illinois. It offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia in pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome. It is also developing XP-8121, a once-weekly subcutaneous injection of levothyroxine that is in phase 3 clinical trial for the treatment of hypothyroidism. The company was incorporated in 2005 and is headquartered in Chicago, Illinois.
More in Drug Manufacturers - Specialty & Generic
TAK
Takeda Pharmaceutical Company L
$56B 12.4% YTD
HLN
Haleon plc
$45B 2.9% YTD
TEVA
Teva Pharmaceutical Industries
$37B 1.5% YTD
ZTS
Zoetis Inc.
$32B -37.4% YTD
UTHR
United Therapeutics Corporation
$26B 7.5% YTD
VTRS
Viatris Inc.
$21B 45.7% YTD
NBIX
Neurocrine Biosciences, Inc.
$18B 28.9% YTD
ELAN
Elanco Animal Health Incorporat
$13B 12.8% YTD
Data is sourced from end-of-day snapshots and refreshed daily before the US market open — nothing on this page is real-time. Figures can contain vendor errors. This page is for information only and is not investment advice.